00013.HK
HUTCHMED (China) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 22.54
+3.02%Sep 3, 2026, 04:12 UTC
Hutchison China MediTech and GlaxoSmithKline reached a licensing agreement for a KRAS-EGFR antibody-drug conjugate cancer drug.
Aug 28, 2026, 00:00 UTC
China's National Medical Products Administration approved HUTCHMED's ATLED (fanregratinib) for the treatment of patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.
Jun 25, 2026, 05:56 UTC
HUTCHMED announced that its registrational Phase 2 trial of Fanregratinib met the primary endpoint in bile duct cancer, and its New Drug Application for the drug was accepted for review and granted priority.
Source: